|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0315 - 0.0343|
|52 Week Range||0.0315 - 0.0900|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Richard Hopkins has been the CEO of Zelira Therapeutics Limited ( ASX:ZLD ) since 2018, and this article will examine...
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding licensing agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC). Under the agreement, Alternative Solutions will produce and distribute the HOPE™ line of products, Zelira's top-selling treatment developed for autism patients, throughout the legal DC medical cannabis market beginning in Q2 2021.